Europe’s drug regulator said On Wednesday it could beat Novavax’s COVID-19 vaccine “within weeks” if the data provided is able to demonstrate the efficacy and safety of the shot, a major boon for the Maryland-based biotech, which has been plagued by manufacturing difficulties. and was not successful till November. Brought a vaccine to market in its 34-year history.
European Medicines Agency (EMA) said It may consider a shot at an accelerated time frame because “a large portion of the data was already reviewed” during the rolling review.
Novavax’s protein-based shot is different from the regulatory-approved four COVID-19 vaccines—made by Pfizer-BioNtech, Moderna, Johnson & Johnson and AstraZeneca—and is made using an age-old technology that can Help Relieve vaccine hesitation in some people.
The jab was first approved for emergency use by regulators in Indonesia in early November and Philippines On Wednesday, both were produced by Serum Institute of India, the world’s largest vaccine manufacturer by volume.
Shares of Novavax climbed more than 8% on Wednesday.